Abstract:
OBJECTIVE:To evaluate total annual all-cause, gastrointestinal-related, and symptom-related healthcare costs among chronic constipation (CC) patients and estimate incremental all-cause healthcare costs of CC patients relative to matched controls. METHODS:Patients aged ≥18 years with continuous medical and pharmacy benefit eligibility in 2010 were identified from the HealthCore Integrated Research Database. CC patients had ≥2 medical claims for constipation (ICD-9-CM code 564.0x) ≥90 days apart or ≥1 medical claim for constipation plus ≥1 constipation-related pharmacy claim ≥90 days apart, and no medical claims for irritable bowel syndrome (IBS). Sub-groups with and without abdominal symptoms were classified according to the presence/absence of abdominal pain (ICD-9-CM code 789.0x) and bloating (ICD-9-CM code 787.3x). Controls without claims for constipation, abdominal pain, bloating, or IBS or constipation-related prescriptions were randomly selected and matched 1:1 with CC patients on age, gender, health plan region, and plan type. Generalized linear models with bootstrapping evaluated incremental all-cause costs attributable to CC, adjusting for demographics and comorbidities. RESULTS:Overall, 14,854 patients (n = 7427 each in CC and control groups) were identified (mean age = 59 years; 75.4% female). Mean annual all-cause costs for CC patients were $11,991 (2010 USD), with nearly half (44.8%) attributable to outpatient services, including physician office visits and other outpatient services (10.0% and 34.8%, respectively). GI-related costs comprised 33.7% of total all-cause costs. Symptom-related costs accounted for 10.5%, primarily driven by costs of other outpatient services (50.6%). Adjusted incremental all-cause costs associated with CC were $3508 per patient per year ($4446 for CC with abdominal symptoms; $2783 for CC without abdominal symptoms), of which 81.0% were from medical services. Incremental cost estimates may be over- or under-estimated due to classification based on claims. CONCLUSIONS:CC imposes a substantial burden in direct healthcare costs in a commercially insured population, mainly attributable to greater use of medical services.
journal_name
J Med Econjournal_title
Journal of medical economicsauthors
Cai Q,Buono JL,Spalding WM,Sarocco P,Tan H,Stephenson JJ,Carson RT,Doshi JAdoi
10.3111/13696998.2013.860375subject
Has Abstractpub_date
2014-02-01 00:00:00pages
148-58issue
2eissn
1369-6998issn
1941-837Xjournal_volume
17pub_type
杂志文章abstract:AIM:To evaluate the cost-effectiveness of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, compared to other clinically used biologics (adalimumab, infliximab, and ustekinumab) in Japan for the treatment of moderate-to-severe psoriasis from the healthcare system (total costs) and patient co-payment ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2018.1532905
更新日期:2018-10-26 00:00:00
abstract:OBJECTIVE:To compare rates of severe relapse and total direct and indirect costs over a 2-year period between US-based employees with multiple sclerosis (MS) who were adherent and non-adherent to disease-modifying drugs (DMDs). METHODS:Employees with ≥1 MS diagnosis (ICD-9-CM: 340.x) and ≥1 DMD pharmacy claim between ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.667027
更新日期:2012-01-01 00:00:00
abstract:BACKGROUND:Many countries have various requirements for local economic analyses to assess the value of a new health technology and/or to secure reimbursement. This study presents a case study of an economic model developed to assess the cost-effectiveness of posaconazole vs standard azole therapy (fluconazole/itraconaz...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.761633
更新日期:2013-01-01 00:00:00
abstract:AIMS:Depression is the most frequent comorbidity reported among patients with rheumatoid arthritis (RA). Comorbid depression negatively impacts RA patients' health-related quality-of-life, physical function, mental function, mortality, and experience of pain and symptom severity. The objective of this study was to asse...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1572015
更新日期:2019-04-01 00:00:00
abstract::Aims: To assess healthcare resource utilization (HCRU) and costs in patients with non-small cell lung cancer treated with the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors afatinib or erlotinib as first-line treatment.Materials and methods: This retrospective analysis used data from three large ad...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2019.1645681
更新日期:2020-01-01 00:00:00
abstract:OBJECTIVE:The objective of the current study was to propose an alternative method for measuring individual operator and peer volumes to use as predictors for adverse outcomes. STUDY DESIGN:A retrospective analysis was performed to assess the volume-outcome relationship for percutaneous coronary intervention (PCI) perf...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696990701815578
更新日期:2008-01-01 00:00:00
abstract:OBJECTIVE:The ECHELON-1 trial demonstrated efficacy and safety of brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD) vs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) as frontline therapy for stage III/IV classical Hodgkin lymphoma. This analysis evaluated the cost-effectiveness o...
journal_title:Journal of medical economics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1080/13696998.2018.1542599
更新日期:2019-02-01 00:00:00
abstract:OBJECTIVE:Systemic lupus erythematosus is a complex autoimmune disease, most frequently affecting women of childbearing age. Women with lupus are at increased risk of pregnancy complications that are exacerbated by active disease. Despite this, their use of medications and hospital resources has not been extensively st...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1066796
更新日期:2015-01-01 00:00:00
abstract:BACKGROUND:Patients with unresectable, metastatic colorectal cancer with wild type Kirsten ras mutational status are eligible for sequential treatments which include monoclonal antibodies as first line (1L), second line (2L), or third line (3L) regimens. OBJECTIVE:To compare the economic outcomes of different sequence...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2013.864973
更新日期:2014-02-01 00:00:00
abstract:OBJECTIVE:Compare long-term costs and outcomes of lurasidone to aripiprazole among adults with schizophrenia in the US who previously failed ≥1 atypical antipsychotic (olanzapine, risperidone, quetiapine, or ziprasidone) based on an indirect comparison of outcomes data from clinical trials. METHODS:A 5-year Markov coh...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2013.807813
更新日期:2013-07-01 00:00:00
abstract:AIMS:In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced (febrile) neutropenia (CIN/FN) from the US payer perspective, (2) simulated how savings enable, on a budget-neutral b...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2020.1833339
更新日期:2020-10-24 00:00:00
abstract:OBJECTIVE:To estimate the annualized differences in direct medical and indirect costs associated with improvement in fibromyalgia (FM) severity among pregabalin-treated patients. METHODS:Data from three clinical trials of pregabalin in patients with FM were modeled; efficacy results were extrapolated. Mean annual cost...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.727930
更新日期:2013-01-01 00:00:00
abstract:OBJECTIVE:A cost analysis of once-daily insulin glargine versus three-times daily insulin lispro in combination with oral antidiabetic drugs (OADs) for insulin-naive type 2 diabetes patients in Germany based on the APOLLO trial (A Parallel design comparing an Oral antidiabetic drug combination therapy with either Lantu...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696990902949614
更新日期:2009-06-01 00:00:00
abstract:BACKGROUND:Approximately 20-30% of Canadians suffer from chronic pain. Guidelines for the management of chronic pain support the use of controlled-release (CR) opioids to treat chronic pain. Although effective in managing chronic pain, oxycodone is associated with high rates of opioid-induced constipation (OIC). The co...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2015.1116992
更新日期:2016-01-01 00:00:00
abstract:OBJECTIVE:To assess the cost-effectiveness of insulin detemir compared with Neutral Protamine Hagedorn (NPH) insulin when initiating insulin treatment in people with type 2 diabetes mellitus (T2DM) in Denmark, Finland, Norway, and Sweden. METHODS:Efficacy and safety data were derived from a 20-week multi-centre random...
journal_title:Journal of medical economics
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.3111/13696998.2013.768999
更新日期:2013-01-01 00:00:00
abstract:OBJECTIVE:To evaluate the cost-effectiveness of biphasic insulin lispro mix 75/25 (LM75/25) and mix 50/50 (LM50/50) compared with a long-acting analog insulin (LAAI) regimen from the perspective of a US healthcare payer. METHODS:A published computer simulation model of diabetes was used to evaluate the cost-effectiven...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.675890
更新日期:2012-01-01 00:00:00
abstract:OBJECTIVES:Non-severe nocturnal hypoglycemic events (NSNHEs) may have a major impact on patients. The objective was to determine how NSNHEs affect diabetes management, sleep quality, functioning, and to assess if these impacts differ by diabetes type or country. METHODS:An internet survey to adults with diabetes in th...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2011.624144
更新日期:2012-01-01 00:00:00
abstract:AIMS:The prevalence of atrial fibrillation (AF) has increased over the past years due to aging of the population, and healthcare costs associated with AF reflect a significant financial burden. The aim of this study was to explore predictors for the real-world AF-related in-hospital costs in patients that recently init...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2017.1363766
更新日期:2017-12-01 00:00:00
abstract:OBJECTIVE:The objective of this study was to analyse hospital incidence of osteogenesis imperfecta (OI) in Spanish hospitals and the associated medical costs from a healthcare system perspective. METHODS:To this aim, a retrospective multicentre study was designed analysing admission records from patients admitted with...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2020.1834402
更新日期:2020-10-21 00:00:00
abstract::Objective: To estimate the cost-effectiveness of utidelone plus capecitabine therapy compared to capecitabine alone in patients with metastatic breast cancer (MBC) resistant to anthracyclines and taxanes treatment in the Chinese context and provide a reference for the marketing of utidelone in China. Methods: A Markov...
journal_title:Journal of medical economics
pub_type: 杂志文章,随机对照试验
doi:10.1080/13696998.2019.1588125
更新日期:2019-06-01 00:00:00
abstract:PURPOSE:To model the economic impact of annual relapses/relapse-related hospitalizations among adults with schizophrenia treated with lurasidone or quetiapine extended-release (XR). METHODS:A probabilistic model estimating per-patient-per-year (PPPY) direct mental healthcare (MH) cost differences due to relapses/relap...
journal_title:Journal of medical economics
pub_type: 杂志文章,随机对照试验
doi:10.3111/13696998.2013.809353
更新日期:2013-08-01 00:00:00
abstract:OBJECTIVE:The spectrum of diseases caused by Streptococcus pneumoniae and non-typeable Haemophilus influenzae (NTHi) represents a large burden on healthcare systems around the world. Meningitis, bacteraemia, community-acquired pneumonia (CAP), and acute otitis media (AOM) are vaccine-preventable infectious diseases tha...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2011.622323
更新日期:2012-01-01 00:00:00
abstract:AIM:Renal failure is a growing public health problem, and is mainly treated by hemodialysis. This study aims to estimate the societal costs of hemodialysis in Lebanon. METHODS:This was a quantitative, cross-sectional cost-of-illness study conducted alongside the Nutrition Education for Management of Osteodystrophy tri...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2016.1207653
更新日期:2016-12-01 00:00:00
abstract:OBJECTIVE:This analysis was conducted to compare the direct medical costs of treatment with darbepoetin alfa every 3 weeks (Q3W) and epoetin alfa every week (QW) in patients with chemotherapy-induced anaemia (CIA) from the payer's perspective. METHODS:An analysis was conducted from a US health plan perspective to comp...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696990801959656
更新日期:2008-01-01 00:00:00
abstract:BACKGROUND AND OBJECTIVES:The cost effectiveness of pregabalin as an add-on to the standard treatment of Belgian patients with post-herpetic neuralgia (PHN) had been demonstrated in a previously published Markov model. The purpose of this study was to update that model with more recent cost data and clinical evidence, ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2013.773333
更新日期:2013-01-01 00:00:00
abstract:AIM:The aim of this analysis was to investigate total healthcare costs, HbA1c, and weight changes over a 36-month period in patients with type 2 diabetes initiated on NPH or long-acting insulin analogs. METHODS:Electronic patient data from 479 general practices in the UK (THIN database) were examined for new users of ...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2014.991788
更新日期:2015-04-01 00:00:00
abstract::Aims: To estimate the budgetary impact of providing additional reimbursement for long acting injections for schizophrenia patients in psychiatric hospital settings in Japan to improve patient outcomes in schizophrenia.Methods: Budget impact analysis of change in reimbursement policy using a prevalence-based model over...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.1080/13696998.2020.1754229
更新日期:2020-08-01 00:00:00
abstract:OBJECTIVE:Duloxetine is indicated for treatment of major depressive disorders in the UK. While clinical trials have documented its clinical effectiveness, little is known regarding the relationship between duloxetine use and healthcare utilization in community practice. This study quantifies the impact of treatment wit...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696998.2012.672941
更新日期:2012-01-01 00:00:00
abstract:OBJECTIVE:Epilepsy surgery is one of the most effective treatments in modern medicine. Yet, it remains largely under-utilized, in spite of its proven efficacy. The referrals for epilepsy surgery are often delayed until it is too late to prevent the detrimental psychosocial effects of refractory seizures. The reluctance...
journal_title:Journal of medical economics
pub_type: 杂志文章,评审
doi:10.1080/13696998.2017.1412975
更新日期:2018-05-01 00:00:00
abstract:OBJECTIVE:Few studies have examined the costs associated with differing first-line chemotherapy regimens in patients with metastatic breast cancer (MBC). This study compares the relative cost impact of women starting first-line chemotherapy with capecitabine versus taxanes. METHODS:Women receiving first-line chemother...
journal_title:Journal of medical economics
pub_type: 杂志文章
doi:10.3111/13696990903269673
更新日期:2009-09-01 00:00:00